New Contracts for Clinical Logistics - Report on Cryoport

Aug 03, 2015, 09:00 ET from

NEW YORK, August 3, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Cryoport, Inc. (NYSE: CYRX). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:

Highlights from our CYRX Report include:

  • Logistics Support to CaRE Arthritis - In a press release dated June 17, 2015, Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, announced that it has been selected to provide comprehensive cryogenic logistics support to CaRE Arthritis and also aid their efforts in the development of personalized care options for arthritis. Cryoport informed that its validated solutions would provide integrity for temperature sensitive shipments, supporting patient access for CaRE Arthritis research and development efforts. 
  • Cryoport and CaRE Arthritis' Management Opinion on the deal - Jerrell Shelton, CEO of Cryoport, said, "We look forward to working with CaRE Arthritis to help them advance their research efforts.  We offer comprehensive as well as best-in-class cryogenic solutions to an industry that needs reliability in order to accelerate forward.  Cryoport is being recognized as a critical partner to the research community from a wide range of organizations." Further, Dr. Walter Maksymowych, Chief Medical Officer of CaRE Arthritis, added, "The development and application of new imaging and biomarker technologies is an essential step to bringing the concept of personalized medicine to reality in the day-to-day management of arthritis.  With the support of Cryoport's cold chain logistics, we are working tirelessly to better understand and efficiently treat the disease."
  • Logistics Provider to Lynden International - In a prior press release dated June 10, 2015, Cryoport reported that Lynden International has chosen the Company as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa. According to Cryoport, its Cryogenic logistics solutions will complement Lynden's cold chain capabilities in support of its shipments of temperature sensitive materials for ongoing clinical trials in Africa. Lynden International is a full-service domestic and international freight forwarder with over 50 offices worldwide, including the United States, Micronesia, Canada, Mexico, Brazil, Russia and the Russian Far East.
  • Cryoport's CEO opinion on deal with Lynden - Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "We are pleased with the opportunity to expand Lynden's capabilities with our validated cryogenic logistics solutions.  We have great experience in clinical trial logistics and look forward to working with Lynden in furthering clinical trial work in Africa for underrepresented diseases.  Our best-in-class cryogenic logistics solutions are a key component to providing the worldwide access that is required by the life science industry to successfully conduct clinical trials around the globe."

To find out how this influences our rating on Cryoport, Inc., read the full report in its entirety here:  

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.